Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

被引：657

作者：

Mavaddat, Nasim ^{[1
]}

Peock, Susan ^{[1
]}

Frost, Debra ^{[1
]}

Ellis, Steve ^{[1
]}

Platte, Radka ^{[1
]}

Fineberg, Elena ^{[1
]}

Evans, D. Gareth ^{[2
]}

Izatt, Louise ^{[3
]}

Eeles, Rosalind A. ^{[4
]}

Adlard, Julian ^{[5
]}

Davidson, Rosemarie ^{[6
]}

Eccles, Diana ^{[7
]}

Cole, Trevor ^{[8
]}

Cook, Jackie ^{[9
]}

Brewer, Carole ^{[10
]}

Tischkowitz, Marc ^{[11
]}

Douglas, Fiona ^{[12
]}

Hodgson, Shirley ^{[13
]}

Walker, Lisa ^{[14
]}

Porteous, Mary E. ^{[15
]}

Morrison, Patrick J. ^{[16
]}

Side, Lucy E. ^{[17
]}

Kennedy, M. John ^{[18
,19
]}

Houghton, Catherine ^{[20
]}

Donaldson, Alan ^{[21
]}

Rogers, Mark T. ^{[22
]}

Dorkins, Huw ^{[23
]}

Miedzybrodzka, Zosia ^{[24
,25
]}

Gregory, Helen ^{[24
,25
]}

Eason, Jacqueline ^{[26
]}

Barwell, Julian ^{[27
]}

McCann, Emma ^{[28
]}

Murray, Alex ^{[28
]}

Antoniou, Antonis C. ^{[1
]}

Easton, Douglas F. ^{[1
]}

机构：

[1] Cent Manchester Univ Hosp NHS Fdn Trust, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Manchester, Lancs, England

[2] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[3] Guys Hosp, South East Thames Reg Genet Serv, London SE1 9RT, England

[4] Inst Canc Res & Royal Marsden NHS Fdn Trust, Oncogenet Team, London, England

[5] Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England

[6] Yorkhill Hosp, Ferguson Smith Ctr Clin Genet, Glasgow, Lanark, Scotland

[7] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England

[8] Birmingham Womens Hosp Healthcare NHS Trust, West Midlands Reg Genet Serv, Birmingham, W Midlands, England

[9] Sheffield Childrens Hosp, Sheffield Clin Genet Serv, Sheffield, S Yorkshire, England

[10] Royal Devon & Exeter Hosp, Dept Clin Genet, Exeter EX2 5DW, Devon, England

[11] Addenbrookes Hosp, East Anglian Reg Genet Serv, Dept Clin Genet, Cambridge, England

[12] Newcastle Tyne Hosp NHS Trust, Ctr Life, Inst Med Genet, Newcastle Upon Tyne, Tyne & Wear, England

[13] St Georges Univ London, Dept Clin Genet, London, England

[14] Churchill Hosp, Oxford Reg Genet Serv, Oxford OX3 7LJ, England

[15] Western Gen Hosp, South East Scotland Reg Genet Serv, Edinburgh EH4 2XU, Midlothian, Scotland

[16] Belfast City Hosp, Northern Ireland Reg Genet Ctr, Belfast BT9 7AD, Antrim, North Ireland

[17] Great Ormond St Hosp Sick Children, North East Thames Reg Genet Serv, London WC1N 3JH, England

[18] Trinity Coll Dublin, Acad Unit Clin & Mol Oncol, Dublin, Ireland

[19] St James Hosp, Dublin, Ireland

[20] Liverpool Womens NHS Fdn Trust, Cheshire & Merseyside Clin Genet Serv, Liverpool, Merseyside, England

[21] South West Reg Genet Serv, Bristol, Avon, England

[22] Univ Wales Hosp, All Wales Med Genet Serv, Cardiff CF4 4XW, S Glam, Wales

[23] Kennedy Galton Ctr, North West Thames Reg Genet Serv, Harrow, Middx, England

[24] NHS Grampian, North Scotland Reg Genet Serv, Aberdeen, Scotland

[25] Univ Aberdeen, Aberdeen, Scotland

[26] Nottingham Univ Hosp NHS Trust, Nottingham Clin Genet Serv, Nottingham, England

[27] Univ Hosp Leicester NHS Trust, Leicestershire Clin Genet Serv, Leicester, Leics, England

[28] Glan Clwyd Gen Hosp, All Wales Med Genet Serv, Rhyl, Wales

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 11期

基金：

英国医学研究理事会;

关键词：

REDUCING SALPINGO-OOPHORECTOMY; CONTRALATERAL BREAST-CANCER; SURGICAL ADJUVANT BREAST; BILATERAL PROPHYLACTIC OOPHORECTOMY; ASHKENAZI JEWISH CARRIERS; OVARIAN-CANCER; GENETIC SUSCEPTIBILITY; GERMLINE MUTATIONS; COMMON VARIANTS; FAMILY-HISTORY;

D O I：

10.1093/jnci/djt095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Reliable estimates of cancer risk are critical for guiding management of BRCA1 and BRCA2 mutation carriers. The aims of this study were to derive penetrance estimates for breast cancer, ovarian cancer, and contralateral breast cancer in a prospective series of mutation carriers and to assess how these risks are modified by common breast cancer susceptibility alleles. Prospective cancer risks were estimated using a cohort of 978 BRCA1 and 909 BRCA2 carriers from the United Kingdom. Nine hundred eighty-eight women had no breast or ovarian cancer diagnosis at baseline, 1509 women were unaffected by ovarian cancer, and 651 had been diagnosed with unilateral breast cancer. Cumulative risks were obtained using KaplanMeier estimates. Associations between cancer risk and covariables of interest were evaluated using Cox regression. All statistical tests were two-sided. The average cumulative risks by age 70 years for BRCA1 carriers were estimated to be 60% (95% confidence interval [CI] 44% to 75%) for breast cancer, 59% (95% CI 43% to 76%) for ovarian cancer, and 83% (95% CI 69% to 94%) for contralateral breast cancer. For BRCA2 carriers, the corresponding risks were 55% (95% CI 41% to 70%) for breast cancer, 16.5% (95% CI 7.5% to 34%) for ovarian cancer, and 62% (95% CI 44% to 79.5%) for contralateral breast cancer. BRCA2 carriers in the highest tertile of risk, defined by the joint genotype distribution of seven single nucleotide polymorphisms associated with breast cancer risk, were at statistically significantly higher risk of developing breast cancer than those in the lowest tertile (hazard ratio 4.1, 95% CI 1.2 to 14.5; P .02). Prospective risk estimates confirm that BRCA1 and BRCA2 carriers are at high risk of developing breast, ovarian, and contralateral breast cancer. Our results confirm findings from retrospective studies that common breast cancer susceptibility alleles in combination are predictive of breast cancer risk for BRCA2 carriers.

引用

页码：812 / 822

页数：11

共 50 条

[21] Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, Kelly
Lynch, Henry T.
Ghadirian, Parviz
Tung, Nadine
Kim-Sing, Charmaine
Olopade, Olufunmilayo I.
Domchek, Susan
Eisen, Andrea
Foulkes, William D.
Rosen, Barry
Vesprini, Danny
Sun, Ping
Narod, Steven A.
BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (01) : 287 - 296
[22] Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, Monika K.
Engel, Christoph
Rhiem, Kerstin
Gadzicki, Dorothea
Bick, Ulrich
Kast, Karin
Froster, Ursula G.
Schlehe, Bettina
Bechtold, Astrid
Arnold, Norbert
Preisler-Adams, Sabine
Nestle-Kraemling, Carolin
Zaino, Mohammad
Loeffler, Markus
Kiechle, Marion
Meindl, Alfons
Varga, Dominic
Schmutzler, Rita K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5887 - 5892
[23] Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K.
Gershman, S.
Lynch, H. T.
Ghadirian, P.
Tung, N.
Kim-Sing, C.
Olopade, O. I.
Domchek, S.
McLennan, J.
Eisen, A.
Foulkes, W. D.
Rosen, B.
Sun, P.
Narod, S. A.
BRITISH JOURNAL OF CANCER, 2011, 104 (09) : 1384 - 1392
[24] Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers
Milne, R. L.
Antoniou, A. C.
ANNALS OF ONCOLOGY, 2011, 22 : i11 - i17
[25] Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Cybulski, Cezary
Lubinski, Jan
Huzarski, Tomasz
Lynch, Henry T.
Randall, Susan Armel
Neuhausen, Susan L.
Senter, Leigha
Friedman, Susan
Ainsworth, Peter
Singer, Christian
Foulkes, William D.
Narod, Steven A.
Sun, Ping
Kotsopoulos, Joanne
BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (02) : 435 - 441
[26] Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
Mulligan, Anna Marie
Couch, Fergus J.
Barrowdale, Daniel
Domchek, Susan M.
Eccles, Diana
Nevanlinna, Heli
Ramus, Susan J.
Robson, Mark
Sherman, Mark
Spurdle, Amanda B.
Wappenschmidt, Barbara
Lee, Andrew
McGuffog, Lesley
Healey, Sue
Sinilnikova, Olga M.
Janavicius, Ramunas
Hansen, Thomas V. O.
Nielsen, Finn C.
Ejlertsen, Bent
Osorio, Ana
Munoz-Repeto, Ivan
Duran, Mercedes
Godino, Javier
Pertesi, Maroulio
Benitez, Javier
Peterlongo, Paolo
Manoukian, Siranoush
Peissel, Bernard
Zaffaroni, Daniela
Cattaneo, Elisa
Bonanni, Bernardo
Viel, Alessandra
Pasini, Barbara
Papi, Laura
Ottini, Laura
Savarese, Antonella
Bernard, Loris
Radice, Paolo
Hamann, Ute
Verheus, Martijn
Meijers-Heijboer, Hanne E. J.
Wijnen, Juul
Garcia, Encarna B. Gomez
Nelen, Marcel R.
Kets, C. Marleen
Seynaeve, Caroline
Tilanus-Linthorst, Madeleine M. A.
van der Luijt, Rob B.
van Os, Theo
Rookus, Matti
BREAST CANCER RESEARCH, 2011, 13 (06)
[27] Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence
Shah, P.
Rosen, M.
Stopfer, J.
Siegfried, J.
Kaltman, R.
Mason, B.
Armstrong, K.
Nathanson, K. L.
Schnall, M.
Domchek, S. M.
BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (03) : 539 - 546
[28] Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients
Su, Liming
Xu, Ye
Ouyang, Tao
Li, Jinfeng
Wang, Tianfeng
Fan, Zhaoqing
Fan, Tie
Lin, Benyao
Xie, Yuntao
INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (12) : 3335 - 3342
[29] The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers
Ko, Kwang-Pil
Kim, Shana J.
Huzarski, Tomasz
Gronwald, Jacek
Lubinski, Jan
Lynch, Henry T.
Armel, Susan
Park, Sue K.
Karlan, Beth
Singer, Christian F.
Neuhausen, Susan L.
Narod, Steven A.
Kotsopoulos, Joanne
INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (11) : 2263 - 2272
[30] Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer
Mainor, C. B.
Isaacs, C.
CURRENT BREAST CANCER REPORTS, 2020, 12 (02) : 66 - 74

← 1 2 3 4 5 →